Products

AISight Dx
PathAI
Pathology AI
AISight Dx is PathAI's FDA-cleared, cloud-native digital pathology image management system that integrates AI algorithms to support laboratory workflows, clinical operations, and primary diagnosis in the US. It streamlines diagnostic workflows, enables precision collaboration, and supports accurate, efficient diagnoses across various settings.

See all 1 product →

About PathAI

PathAI is a leading healthcare AI company specializing in precision pathology, dedicated to improving patient outcomes through advanced artificial intelligence. The company develops robust, versatile solutions that leverage deep computational and medical expertise to optimize the analysis of patient tissue samples. Their core mission is to enhance diagnostic accuracy, accelerate drug development, and facilitate the matching of patients with the most effective treatments, particularly in complex diseases like cancer.

The company’s flagship platform, AISight®, is a cloud-native intelligent enterprise workflow solution designed for digital pathology. It serves as a central hub for case and image management, integrating best-in-class AI tools for various histopathology use cases. PathAI’s technology applies machine and deep learning techniques to vast datasets, including over 32.5 million expert annotations from a proprietary and crowd-sourced network of over 450 pathologists, to rigorously train and validate its AI-based models. This enables precise identification and quantification of pathological features, supporting pathologists in managing workloads and improving diagnostic standards.

PathAI collaborates extensively with biopharmaceutical companies, diagnostic laboratories, and academic medical centers, offering a comprehensive suite of services. These include AI-powered translational research for biomarker and drug discovery, end-to-end clinical trial pathology services, and support for diagnostic development and commercialization. Their solutions aim to unlock novel insights into disease pathophysiology, biomarker expression, and drug response at the tissue and cellular level, ultimately driving precision medicine forward.

Focus Areas

AI-powered pathology digital pathology cancer diagnosis drug development biomarker discovery clinical trials precision medicine oncology MASH/MASLD IBD dermatopathology image management systems computational pathology explainable AI

Business Intelligence

Key InvestorsGeneral Catalyst, General Atlantic, Tiger Global Management, D1 Capital Partners, Kaiser Permanente, LabCorp, Bristol-Myers Squibb Company, Merck Global Health Innovation Fund, 8VC, Adage, Biospring Partners, KdT Ventures, Polaris Partners, Refactor Capital, Pillar VC
PartnershipsQuest Diagnostics (2024), MedStar Health (2026), Roche Tissue Diagnostics (expanded 2024), ConcertAI (2023), Agilent Technologies (2023), Foundation for the National Institutes of Health's Biomarkers Consortium (2023), University Hospital Zurich (2026), UMC Utrecht (2025), Labcorp (expanded 2026), Northwestern Medicine (2025), Precision for Medicine (2025), Deep Bio (2024), DoMore Diagnostics (2024), Paige (2024), Visiopharm (2024)
AcquisitionsPoplar Healthcare (2021)
TechnologyAISight® Dx digital pathology platform, cloud-native, AI-powered research platform, machine learning, deep learning, computer vision, AI operating system, Predetermined Change Control Plan (PCCP), PLUTO foundation model
FDA Clearances1 cleared products (estimated)

What Physicians Need to Know

AI-Powered Pathology & Digital Pathology
PathAI specializes in transforming traditional pathology with AI, offering a cloud-native digital pathology platform, AISightu00ae Dx, which centralizes case and image management. This platform enables pathologists to view, interpret, share, and manage whole slide images intuitively, integrating AI for enhanced workflows.
Cancer Diagnosis & Oncology
The company develops AI algorithms for various oncology applications, including tumor detection, grading, and quantification of key biomarkers like PD-L1, HER2, ER, PR, and Ki-67. Their tools also provide spatial analysis of the tumor microenvironment to unlock deeper insights into cancer biology.
Drug Development & Clinical Trials
PathAI offers comprehensive AI-powered solutions for every phase of drug and diagnostic development. This includes translational research, biomarker discovery, patient stratification, and standardized endpoint measurement in clinical trials, supported by end-to-end pathology lab services.
MASH/MASLD (Metabolic Dysfunction-Associated Steatohepatitis/Liver Disease)
PathAI provides AIM-MASH AI Assist, an AI-powered tool for accurate and reproducible histologic assessment, scoring, and staging of MASLD and MASH. This tool is qualified by the EMA and has received FDA qualification for MASH clinical trials, aiding pathologists in reducing scoring variability.
IBD (Inflammatory Bowel Disease)
For IBD, PathAI offers AIM-HI UC for automated and reproducible Geboes scoring in ulcerative colitis, and IBDExplore, an AI-powered panel that spatially characterizes the inflammatory microenvironment from H&E whole slide images, aiding in biomarker discovery and treatment target identification.
Dermatopathology
PathAssist Derm is an AI-assisted tool designed for dermatopathology research, accelerating workflows by automating specimen orientation, prioritization, and measurement. It has received FDA Breakthrough Device Designation, recognizing its potential to aid in the review of digital whole-slide images of skin lesions.
Image Management Systems
AISightu00ae Dx is PathAI's FDA-cleared and CE-IVD marked cloud-native digital pathology image management system for primary diagnosis. It streamlines diagnostic workflows, enables precision collaboration, and supports high-throughput, AI-enabled research by centralizing case and image management.
Computational Pathology & Explainable AI (xAI)
PathAI leverages advanced computational pathology techniques, including deep learning, convolutional neural networks (CNNs), graph neural networks (GNNs), and multiple instance learning (MIL). A key focus is Explainable AI (xAI), which provides transparent and interpretable insights, justifying AI results to build trust and understanding.
Physician Tip

For physicians, PathAI's solutions are designed to augment, not replace, their expertise. The AI-powered tools offer improved diagnostic accuracy and consistency by reducing inter- and intra-observer variability, leading to more reliable diagnoses. Pathologists can benefit from enhanced workflow efficiency through automated tasks like specimen orientation, case prioritization, and faster turnaround times. The platform provides deeper insights and facilitates biomarker discovery by extracting quantitative and spatial features from H&E slides, which can lead to a better understanding of disease pathophysiology. Crucially, PathAI's Explainable AI features provide visual overlays and justifications for AI predictions, empowering pathologists with confidence and a clear understanding of the AI's reasoning. This ultimately supports precision medicine by aiding in matching patients with the most effective treatments and accelerating drug development, leading to improved patient outcomes. The FDA clearances and designations for their platforms and algorithms further instill clinical confidence in the reliability and utility of these advanced tools. The cloud-native nature of AISight also enables seamless collaboration and remote access, which is increasingly vital in modern pathology practice.

PathAI's AISightu00ae platform is built as a cloud-native, open enterprise workflow solution, emphasizing broad interoperability. It is designed to integrate seamlessly with major Laboratory Information Systems (LIS/LIMS) and supports various slide scanners from leading vendors such as Leica Aperiou00ae, Hamamatsu NanoZoomeru00ae, and Roche VENTANAu00ae. PathAI actively fosters strategic partnerships across the digital pathology ecosystem to ensure its solutions can be easily adopted and integrated into diverse laboratory environments.

Products by PathAI

1 product in the directory

AISight Dx
PathAI
Pathology AI
AISight Dx is PathAI's FDA-cleared, cloud-native digital pathology image management system that integrates AI algorithms to support laboratory workflows, clinical operations, and primary diagnosis in the US. It streamlines diagnostic workflows, enables precision collaboration, and supports accurate, efficient diagnoses across various settings.

What the Web Says

PathAI is a company focused on improving patient outcomes through AI-powered pathology solutions, offering services from wet lab to algorithm deployment for clinical trials and diagnostics. Their platform utilizes AI to analyze high-resolution pathology slides, classify tissues, and compile diagnostic reports, aiming to enhance diagnostic efficiency and accuracy while accelerating drug development. The company has received regulatory approvals for select clinical diagnostic and research use cases globally, including FDA Breakthrough Device Designation for PathAssist Derm and 510(k) clearance for AISightu00ae Dx2. Employer reviews indicate a mission-driven culture with strong engineering talent, but also highlight challenges related to growth, management, and work-life balance for some roles.

Overall: Mixed

Strengths

  • Top-notch mission and technology, with a singular vision.
  • High-grade enterprise security and compliance standards for their product.
  • Unrivaled tissue and cell classification depth.
  • Saves time on manual slide analysis and reporting.
  • Good compensation and benefits.
  • Positive work culture with great team cohesion and opportunities for learning.

Limitations

  • Growing pains typical of a company their size and age in an evolving, competitive industry.
  • Disorganized and toxic vibe reported by some employees, with budgeting worries.
  • Management's unfamiliarity with lab instruments and HR's mishandling of serious issues.
  • Brutal and hard-to-adjust-to hours for some roles, like Pathologists' Assistants.
  • Product requires custom enterprise contract configurations, leading to a high barrier to entry.
  • Model outputs require clinical verification against source slides.

Based on reviews from: Indeed.com, Comparably, Elion Health, Great Place To Worku00ae, Build Fast with AI, Reddit, Becker's Hospital Review

Last updated: 2026-07-22

Videos

News, demos, and interviews about PathAI.

Loading videos...

Videos load interactively. If none appear, search YouTube for PathAI →

View all on YouTube

Press & Coverage

Imaging Technology News
Roche to Acquire PathAI to Expand Digital Pathology and AI Diagnostics
Roche has entered into a definitive merger agreement to acquire PathAI for an upfront purchase price of $750 million, with additional milestone payments of up to $300 million. This acquisition aims to integrate PathAI's AI-powered technology and image management systems into pathology laboratory workflows to improve cancer diagnosis and tailored treatment.
2026-05
PathAI Press Release
PathAI Receives U.S. FDA Breakthrough Device Designation for PathAssist Derm, an AI-Powered Pathology Solution to Transform Dermatopathology Workflow
PathAI announced that the U.S. FDA has granted Breakthrough Device Designation to PathAssist Derm, an AI-powered solution designed to analyze digital pathology whole slide images of skin lesions and assist pathologists. This follows previous regulatory achievements, including 510(k) clearance for AISightu00ae Dx.
2026-03
PathAI Press Release
PathAI and MedStar Health Announce Partnership to Deploy the AISightu00ae Dx Digital Pathology Platform and Advanced AI Applications
PathAI and MedStar Health announced a multi-year strategic collaboration to deploy PathAI's AISightu00ae Dx Digital Pathology Platform and AI algorithm products across MedStar Health's network. This partnership aims to transform pathology workflows through enterprise-scale slide management, viewing, and AI integration.
2026-04
PathAI Press Release
PathAI Receives FDA Clearance for AISightu00ae Dx Platform for Primary Diagnosis
PathAI received 510(k) clearance from the U.S. FDA for its AISightu00ae Dx digital pathology image management system for use in primary diagnosis in clinical settings. This clearance includes a Predetermined Change Control Plan (PCCP) to accelerate future software updates and hardware integrations.
2025-06
PathAI Press Release
PathAI and Northwestern Medicine Announce Strategic Collaboration to Deploy the AISightu00ae Digital Pathology Platform and Co-Develop New AI Diagnostics
PathAI and Northwestern Medicine announced a strategic collaboration to transform pathology diagnostics through artificial intelligence, including the deployment of PathAI's AISightu00ae digital pathology platform and joint research efforts. This partnership will enable remote case review and explore new AI applications in digital pathology.
2025-06
PathAI Press Release
PathAI Announces Completion of $165 Million Financing for Advancing Medicine with AI-powered Pathology
PathAI closed its $165 million Series C financing round, co-led by D1 Capital Partners and Kaiser Permanente. The funds will be used to accelerate product development, expand the PathAI product suite, and enhance its commercial footprint.
2021-05
General Atlantic
PathAI Secures $60M in Series B Funding Led by General Atlantic and Existing Investor General Catalyst
PathAI raised $60 million in Series B funding, led by General Atlantic with strong participation from General Catalyst. This capital will fuel PathAI's expansion to advance the medical discipline of pathology and enhance offerings to existing partners.
2019-04
PMC (via npj Precision Oncology)
Digital pathology and artificial intelligence in translational medicine and clinical practice
This peer-reviewed article discusses the role of digital pathology and AI in translational medicine and clinical practice, highlighting how AI models generated on the PathAI platform can improve tumor purity estimation and enhance diagnostic accuracy.
2021-10

Frequently Asked Questions

PathAI's AISightu00ae Dx platform, an FDA-cleared digital pathology image management system, integrates AI tools like TumorDetect to automate tumor assessment and prioritize cases, aiming to improve diagnostic accuracy and efficiency. This system streamlines workflows by providing pathologists with AI-generated insights and quantitative metrics, helping to expedite case review and accelerate downstream testing.
PathAI offers comprehensive BioPharma services, leveraging AI models like PathExplore to unlock novel insights from tissue samples for biomarker discovery and drug response prediction in oncology, MASH, and IBD. Their platforms and services enable clinical trial success through trial-ready algorithms, comprehensive lab services, and integration with central lab providers, accelerating the identification of effective treatments.
PathAI provides specialized AI tools such as AIM-MASH AI Assist, which has received FDA and EMA qualification for MASH clinical trials, and AI.Dx MASH, an AI-assisted LDT for MASLD/MASH histologic scoring. For IBD, they offer solutions like AIM-HI-UC, and for dermatopathology, PathAssistDerm is available, all designed to enhance diagnostic precision and reduce variability.
PathAI's AISightu00ae is a cloud-native, interoperable image management system that serves as a central hub for case and image management, integrating PathAI and third-party AI algorithms. To address explainable AI concerns, PathAI has developed frameworks like HIPPO, which systematically modifies tissue regions to provide deeper insights into model behavior and enhance trust in AI predictions.
PathAI holds ISO 13485 and ISO 27001 certifications, demonstrating its commitment to quality management and information security. Their AISightu00ae Dx platform is FDA-cleared for primary diagnosis, and AIM-MASH AI Assist has received FDA and EMA qualification for clinical trial use. PathAI implements commercially reasonable safeguards, including encryption and access controls, to protect personal and sensitive information.
PathAI actively forms strategic partnerships with leading cancer centers, diagnostic labs, and biopharma companies like Moffitt Cancer Center, Quest Diagnostics, and Precision for Medicine to expand its reach and co-develop AI diagnostics. The company is well-funded with a valuation over $1 billion and projects significant revenue growth, driven by expanding clinical digital pathology adoption and multi-year agreements, indicating strong company stability and promising future prospects.

Investors

Who's funded PathAI.

Khazanah Nasional Ventures
PE AI T2
Kuala Lumpur, Malaysia
$25M+
Khazanah Nasional is the sovereign wealth fund of Malaysia, with a venture-and-growth investing program that includes high-value strategic healthcare technology investments. Stage…
Life Sciences Tools Pharma / Therapeutics
Anchorless Bangladesh
VC AI T2
Dhaka, Bangladesh
$250k-$1M
Anchorless Bangladesh is a specialized firm investing exclusively in Bangladeshi technology companies, with a thesis of empowering local founders to build transformative,…
Digital Health Health IT / Healthcare Software
Pillar VC
VC T1
Boston, United States
$1M-$5M
Pillar VC is a Boston-based seed and early-stage firm that has built one of the most credible founder-first franchises in the New…
AI/ML in Healthcare Biotech
Verge Healthtech Fund
VC T3
Singapore, Singapore
$250k-$1M
Verge Healthtech Fund is a Singapore-based early-stage healthtech specialist at verge.fund with a Singapore LinkedIn presence and active Crunchbase profile, focused on…
AI/ML in Healthcare Diagnostics
Refactor Capital
VC T3
Burlingame, United States
$1M-$5M
Refactor Capital is an early-stage venture firm whose name has historically signaled a focus on rebuilding industries that have resisted software, with…
Biotech Care Delivery / Tech-Enabled Services
Polaris Partners
VC T3
Boston, United States
unknown
Polaris Partners is a Boston-based, multi-stage investment firm with deep healthcare and life-sciences expertise, having backed category-leading therapeutics, devices, diagnostics and digital…
AI/ML in Healthcare Biotech
Necessary Ventures
VC T3
San Francisco, United States
$1M-$5M
Necessary Ventures is an early-stage venture firm with a website and a public footprint that suggests a small, conviction-driven seed investor with…
AI/ML in Healthcare Biotech
Merck
Corporate VC T3
Rahway, United States
$1M-$5M
Merck operates a complex set of corporate venture and strategic capital vehicles, including Merck Global Health Innovation Fund and the company’s broader…
AI/ML in Healthcare Diagnostics
Lightbank
VC T3
Chicago, United States
unknown
Lightbank is the Chicago-based early-stage venture firm founded by the Groupon founders, focused on B2B software, marketplaces, and consumer internet companies in…
AI/ML in Healthcare Biotech
IAG Capital Partners
VC T3
Charleston, United States
unknown
IAG Capital Partners is a Tulsa-based investment firm with a generalist private equity and venture orientation, including selective exposure to healthcare services…
AI/ML in Healthcare Biotech

Related Companies

Visiopharm is a leading provider of AI-driven precision pathology software, catering to both research and diagnostic applications. For physicians, Visiopharm offers advanced tools that transform pathology through image analysis, aiming to enhance precision and productivity in pathology labs. The company has developed nine diagnostic algorithms cleared under IVDR for EU and UK customers, which provide […]

TSI (Transworld Systems Inc.) is a long-standing company primarily known for its debt collection and business process outsourcing services. While they serve various industries, including healthcare, their core offering is focused on accounts receivable management and collections rather than healthcare-specific AI development. They provide solutions to help healthcare providers manage patient accounts, improve cash flow, […]

TrialX is a healthcare AI company specializing in clinical research and space health informatics. The company develops platforms designed to connect patients with clinical trials and facilitate research data collection. Their offerings include an enterprise patient recruitment platform (iConnect) that provides a clinical trials finder (Dory), study website builders, pre-screeners, referral tracking, and volunteer registries. […]

Thinkitive is a global IT services and solutions company that specializes in digital transformation, enterprise application services, outsourced product development, and a testing center of excellence. For physicians, Thinkitive offers a range of AI-driven healthcare solutions designed to streamline clinical and administrative workflows, enhance patient care, and improve operational efficiency. Their services include custom healthcare […]

Taction Software is a U.S.-based healthcare IT and custom software development company specializing in HIPAA-compliant solutions. They build AI-powered applications for healthcare, ranging from rapid clinical AI prototypes to production-grade systems with EHR integration, ambient documentation, and predictive analytics. The company focuses on transforming healthcare delivery through secure, compliant, and innovative software solutions that aim […]

SUPERWISE offers an enterprise AI governance and operations platform designed to help organizations, including those in healthcare, deploy and manage autonomous AI systems with oversight and control. The platform addresses governance, compliance, and operational challenges associated with AI and machine learning deployments. It features real-time guardrails for AI systems, model observability capabilities, and compliance automation, […]

AI Tool Finder
AI-powered search. Results may not be comprehensive.